reports
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financi...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted shar...
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences Announces Key Executive Leadership Appointments Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industry PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead...
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financi...
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026 PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on th...
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Mor...
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under . Abo...
Integra LifeSciences Leadership to Present at the Citi 2025 Global Hea...
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under . About Integra LifeSciencesAt Integra LifeSc...
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare ...
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. All Integra dermal regenerative templates, decellularized dermal scaffolds and amniotic tissue membranes, ...
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA...
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair. In addition to cardiac surgery, the CUSA Clarity Ultrasonic Surgical Aspirator System is ind...
Integra LifeSciences Reports Third Quarter 2025 Financial Results
Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year. Adjusted earnings per diluted s...
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conf...
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive dia...
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at t...
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post PRINCETON, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce its exhibition at the CNS Annual Meeting, from October 11 through 15, 2025, in Los Angeles, California. The company’s booth will spotlight its industry-leading products, while featuring two recent additions to the portfolio - and . Durepair Dura...
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan S...
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences: Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ETMorgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET A live webcast of the pr...
Integra LifeSciences Reports Second Quarter 2025 Financial Results
Integra LifeSciences Reports Second Quarter 2025 Financial Results PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $...
Integra LifeSciences to Host Second Quarter 2025 Financial Results Con...
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025 PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive dial-in...
Integra LifeSciences Announces First Patient Enrolled in Acclarent AER...
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world clinical performance of AERA in pediatric patients with obstructive Eustachian tube dysfunction (ETD). Dr....
Integra LifeSciences Reports First Quarter 2025 Financial Results
Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55...
Integra LifeSciences to Host First Quarter 2025 Financial Results Conf...
Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025 PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive dial-in detail...
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthc...
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at . About Integra LifeSciencesAt Integra LifeScien...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financi...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per dilut...
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financi...
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025 PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on...
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.